COVID-19 Infection Clinical Trial
— THROMBOVIDOfficial title:
Study of Hemostasis in Case of Severe COVID-19
NCT number | NCT04359992 |
Other study ID # | 7774 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 17, 2020 |
Est. completion date | May 1, 2021 |
The COVID-19 outbreak has led to a significant increase in the number of patients admitted to
intensive care for respiratory distress. Early data indicate a particularly high risk of
thrombotic risk to viral lung disease, particularly in the most severe patients, with a
particularly high incidence of pulmonary embolism. Catheter thrombosis and extra-renal
purification filters are also abnormally common. These thrombotic complications could
contribute to the mortality observed in this pathology. The introduction of early curative
anticoagulation in the most severe patients has just been proposed by the perioperative
hemostasis interest group
Biologically, a significant proportion of patients hospitalized in intensive care have a
marked biological inflammatory syndrome, associated with signs of activation of clotting (a
frank increase in D-dimers). The presence of circulating anticoagulants is common.
Interestingly, thrombocytosis, normally observed in such inflammatory syndromes, is absent.
In this context, it seems legitimate to explore these patients from a hemostasis perspective
to identify the factors that cause this thrombotic over-risk, in order to minimize the
occurrence of these complications.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | May 1, 2021 |
Est. primary completion date | April 17, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult patient (<18y) - With a SARS-CoV-2 infection confirmed by RT-PCR - Hospitalized in intensive care Exclusion Criteria: - Patients under guardianship/curator - Anemia at 7 g/dL at inclusion |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Strasbourg, France |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Platelet activation intensity with the occurrence of clinical thrombotic complications | Change of platelet activity from admission's day in intensive care unit to 2 days and 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04997551 -
Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19
|
Phase 3 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Completed |
NCT05049226 -
Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine
|
Phase 2 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Terminated |
NCT04455815 -
A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
|
Phase 2 | |
Completed |
NCT04662437 -
The Status of Parathyroid Hormone Secretion in Covid-19 Patients
|
||
Recruiting |
NCT05792878 -
Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
|
||
Completed |
NCT04659200 -
Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
|
||
Recruiting |
NCT04470583 -
Evaluating Clinical Parameters of COVID-19 in Pregnancy
|
||
Withdrawn |
NCT04377568 -
Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children
|
Phase 2 | |
Completed |
NCT04848610 -
The Factors That Affect the Infection of COVID-19
|
||
Recruiting |
NCT04582903 -
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
|
||
Recruiting |
NCT06032000 -
Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)
|
Phase 1 | |
Terminated |
NCT04941703 -
"CHANGE COVID-19 Severity"
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04639466 -
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
|
Phase 1/Phase 2 | |
Completed |
NCT04575038 -
CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
|
Phase 2 | |
Recruiting |
NCT05022446 -
The Impact of COVID-19 on Pulmonary Procedures
|
||
Completed |
NCT04347798 -
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
|
||
Active, not recruiting |
NCT04650178 -
Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
|
||
Recruiting |
NCT04169542 -
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
|